Drug Shortage Report for SODIUM BICARBONATE INJECTION, USP

Last updated on 2021-08-17 History
Report ID 143253
Drug Identification Number 02486636
Brand name SODIUM BICARBONATE INJECTION, USP
Common or Proper name Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq (mmol), 50 mL Vial
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) SODIUM BICARBONATE
Strength(s) 84MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 50 mL
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2021-08-01
Actual start date
Estimated end date 2021-08-16
Actual end date 2021-08-16
Shortage status Resolved
Updated date 2021-08-17
Company comments Fresenius Kabi Canada Ltd. regrets to advise that due to a production delay, our Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq (mmol), 50 mL Vial will be going on backorder, effective August 1, 2021 until August 20, 2021. Omega is an alternate supplier of Sodium Bicarbonate Injection, USP, 8.4% and has been informed of our impending supply interruption.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v6 2021-08-17 English Compare
v5 2021-08-16 French Compare
v4 2021-08-16 English Compare
v3 2021-08-02 English Compare
v2 2021-07-29 French Compare
v1 2021-07-29 English Compare

Showing 1 to 6 of 6